Your session is about to expire
← Back to Search
Nivolumab for Head and Neck Cancer
Study Summary
This trial will test whether the immunotherapy drug nivolumab is safe and effective in people with head and neck cancer who have already had surgery and radiation.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I've had the required scans before surgery, including a PET/CT and CT or MRI of the neck.My health status and lab results meet the required standards.I can provide samples from my previous biopsy or surgery.I had radiation therapy (and possibly surgery or chemotherapy) and a follow-up surgery aiming for a cure, with no other treatment options left.I have not had radiotherapy as my main cancer treatment.I have cancer in my nasal area or upper throat.My cancer has spread to other parts of my body.I still have visible cancer after surgery or had surgery to ease symptoms.
- Group 1: Nivolumab
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you elucidate on the research already done with Nivolumab?
"Presently, there are 718 active studies involving Nivolumab. Out of those trials 82 have advanced to phase 3 and 40237 trial sites across the world are running research for this medication with most located in Basel, BE."
Is this experiment a pioneering endeavor in its field?
"At present, 718 active clinical trials related to Nivolumab are being conducted in 2354 cities and 49 countries. This drug has been studied heavily since its initial trial sponsored by Ono Pharmaceutical Co. Ltd in 2012 which included 659 participants completing Phase 1 & 2 of the approval process. Subsequently, a total of 252 subsequent studies have taken place."
Has Nivolumab obtained regulatory approval from the Food and Drug Administration?
"Taking into consideration the Phase 2 nature of this experiment, our team has assigned Nivolumab a safety rating of 2 due to existing evidence regarding its security profile but lack thereof pertaining to efficacy."
What conditions is Nivolumab typically administered to alleviate?
"Nivolumab can be employed to treat potentially deadly neoplasms, unresectable melanoma, and squamous cell carcinoma."
Is enrollment still open for this investigation?
"Unfortunately, this clinical trial is not presently accepting participants; the last update was made on October 3rd 2022. If you're in search of other studies related to head and neck cancer, there are 481 trials that may suit your needs; similarly, 718 trials using Nivolumab as an intervention are actively recruiting right now."
How many individuals have enrolled in this clinical trial?
"Unfortunately, the trial is currently not accepting any more applicants. It was posted on December 6th 2017 and last updated October 3rd 2022. If you are searching for clinical studies related to head and neck cancer, there are 481 I trials; if Nivolumab interests you, then 718 studies may be suitable."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger